Evidence map›Paper›PMID 38406775›Full record

ArticleJournal of medicine and life2023

Regorafenib modulation of the angiopoietin/TIE2 axis in a mouse model of sepsis-induced lung injury.

Mohammed Hamzah Ibadi, Sahar Majeed, Fadhaa Abdulameer Ghafil, Najah Rayish Hadi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicine and life, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 64% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mohammed Hamzah IbadiBabylon Health Directorate, Babylon, Iraq.
Sahar MajeedDepartment of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq.
Fadhaa Abdulameer GhafilDepartment of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq.
Najah Rayish HadiDepartment of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq.
University of Kufa · IQUniversity of Babylon · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis, often resulting from an immune response overreaction to microorganisms and their products, can lead to acute lung injury through inflammation mediated by excessive cytokines. This study aimed to investigate the effects of regorafenib on lung injury in mice following the induction of sepsis. We divided mice into four groups (n=6 each): a sham group (undergoing laparotomy without cecal ligation and puncture [CLP]), a CLP group, a vehicle group, and a regorafenib-treated group (30 mg/kg IP, administered one hour before CLP). TNF-α, IL-1β, VEGF, MPO, caspase-11, and Ang-2 levels were significantly increased (p<0.05) in the CLP group compared to the sham group, while the regorafenib group showed significant reductions in these markers

Indexed as

Acute Lung InjuryPhenylurea CompoundsPyridinesSepsisAngiopoietinsAnimalsLungMiceRNA, MessengerTumor Necrosis Factor-alphaAngiopoietinsPhenylurea CompoundsPyridinesregorafenibRNA, MessengerTumor Necrosis Factor-alphaAng: AngiopoietinAng/TIE2 axiscadherinCLPCLP: Cecal Ligation and PunctureHKG: Housekeeping GeneIL-1β: Interleukin-1 betaMPO: MyeloperoxidaseNF-κB: Nuclear Factor kappa-light-chain-enhancer of activated B cellsqPCR: Quantitative Real-Time PCRregorafenibsepsisTIE2: Tyrosine Kinase with Immunoglobulin-like and EGF-like Domains 2TNF-α: Tumor Necrosis Factor-alphaVEGFVEGF: Vascular Endothelial Growth Factor

Identifiers

PMID38406775
PMCPMC10893570
OpenAlexW4394741187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.